PMV Pharmaceuticals: Doubles in Nasdaq debut

Prelude Therapeutics Incorporated

25/09/2020 18:37

** PMV Pharmaceuticals Inc  PMVP.O  almost doubles to $35.3
after its Nasdaq debut on Friday
    ** Co raised $211.8 million in IPO, after it was priced at
higher end of range at $18/shr
    ** Post IPO, co valued at $773.99 million
    ** Prelude Therapeutics Inc  PRLD.O  and Graybug Vision
 GRAY.O  also debuted on Friday and gained 33% and 18.75%
respectively at open
    ** Goldman Sachs, BofA Merrill Securities, Cowen and
Evercore were lead financial advisors for PMV 

 (Reporting by Supriya Rangarajan in Bengaluru)
 ((SupriyaR1@thomsonreuters.com; within U.S. +1 646 223 8780;
outside U.S. +91 80 6182 2256;))